Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies

作者全名："Liu, Yashu; Li, Yuting; Du, Hanghang"

作者地址："[Liu, Yashu; Li, Yuting] Chongqing Med Univ, Banan Hosp, Dept Dermatol, Chongqing, Peoples R China; [Du, Hanghang] Xian Huamei Aesthet & Plast Hosp, Xian, Shanxi, Peoples R China"

通信作者："Du, HH (通讯作者)，Xian Huamei Aesthet & Plast Hosp, Xian, Shanxi, Peoples R China."

来源：POSTEPY DERMATOLOGII I ALERGOLOGII

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000938577000026

JCR分区：Q3

影响因子：1.4

年份：2023

卷号：40

期号：1

开始页：165

结束页：170

文献类型：Article

关键词：apremilast; psoriasis; efficacy; safety; randomized controlled trials

摘要："Introduction: The efficacy of apremilast for psoriasis remains controversial. \Aim: We have conducted a systematic review and meta-analysis to explore the influence of apremilast on treat- ment efficacy for psoriasis.Material and methods: We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library data-bases for randomized controlled trials (RCTs) published until February 2022 and assessing the efficacy and safety of apremilast for psoriasis. This meta-analysis was performed using the random-effects model.Results: Seven RCTs were included in the meta-analysis. Overall, compared with placebo for psoriasis, apremi- last was associated with improved PASI-75 (LOCF) (OR = 6.59; 95% CI: 4.55 to 9.53; p < 0.00001), PASI-75 (NRI) (OR = 6.99; 95% CI: 4.43 to 11.04; p < 0.00001), sPGA response (LOCF) (OR = 5.58; 95% CI: 3.82 to 8.16; p < 0.00001), sPGA response (NRI) (OR = 6.06; 95% CI: 4.07 to 9.02; p < 0.00001), PASI-50 (LOCF) (OR = 4.37; 95% CI: 2.72 to 7.01; p < 0.00001), PASI-90 (LOCF) (OR = 7.81; 95% CI: 2.89 to 21.08; p < 0.0001), adverse events (OR = 1.58; 95% CI: 1.19 to 2.10; p = 0.002), but demonstrated no increase in serious adverse events (OR = 1.01; 95% CI: 0.43 to 2.33; p = 0.99). Conclusions: Apremilast is effective and safe to treat psoriasis."

基金机构：　

基金资助正文：